AW
CBIO

Avion Wealth’s Crescent Biopharma CBIO Stock Holding History

Avion Wealth’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40
Closed – – 1380
2025
Q4 		$0 Buy
+40
New +$510 ﹤0.01% 1365

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Avion Wealth's CBIO Position: Q1 2026 in Review

Avion Wealth sold out of Crescent Biopharma (CBIO) in Q1 2026, closing a stake of 40 shares.

Avion Wealth first reported a position in CBIO in Q4 2025 and held it in 1 quarter. The position peaked at $0 in Q4 2025. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Avion Wealth reported no remaining Crescent Biopharma position as of Q1 2026 after selling out during the quarter.
  • Avion Wealth sold 40 Crescent Biopharma shares in Q1 2026.
  • Avion Wealth first reported a position in Crescent Biopharma in Q4 2025 and held it in 1 quarter.
  • Avion Wealth's Crescent Biopharma position peaked at $0 in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Avion Wealth's 13F filing for Q1 2026, filed 1 May 2026.